Abstract

To investigate the longitudinal changes in circumpapillary capillary density (cpCD) and retinal nerve fiber layer thickness (cpRNFLT) and their association with visual field (VF) progression in open-angle glaucoma (OAG) eyes at different stages of glaucoma. Retrospective, observational case series METHODS: This study enrolled 158 eyes of 158 OAG patients classified into early (89 eyes) and moderate-to-advanced (69 eyes) stage based on VF mean deviation (MD; -6 dB). Serial cpCD and cpRNFLT measurements were performed using optical coherence tomography (OCT) angiography and OCT during a mean follow-up of 2.66 years. The reference standard of glaucoma progression was determined by VF progression. The rates of longitudinal change in cpCD and cpRNFLT were evaluated using linear mixed effects models and compared between progressors and nonprogressors. The factors associated with VF progression, including the rates of longitudinal change in cpCD and cpRNFLT, were assessed using logistic regression analyses. The rate of longitudinal change in cpCD was significantly faster in progressors (-1.25% ± 1.15% per year for early stage and -1.61% ± 1.04% per year for moderate-to-advanced stage) than in nonprogressors (0.04% ± 1.12% per year for early stage and -0.34% ± 0.97% per year for moderate-to-advanced stage) regardless of glaucoma stage (all, P < .05). The rates of longitudinal change in cpRNFLT (-0.85 ± 1.20 µm/y vs -0.70 ± 1.02 µm/y, P=.396) did not differ between progressors and nonprogressors in eyes with moderate-to-advanced glaucoma. In multivariable logistic regression analyses, a faster rate of cpCD loss (odds ratio [OR] 0.244, P=.009) had a significant association with VF progression in eyes with moderate-to-advanced glaucoma, whereas faster rates of both cpCD (OR 0.340, P=.012) and cpRNFLT (OR 0.155, P=.031) loss were significantly associated with VF progression in eyes with early-stage glaucoma. In OAG eyes, the rate of longitudinal cpCD loss was significantly associated with VF progression regardless of glaucoma stage.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.